Developing peptide and oligonucleotide APIs demands a precise balance of efficiency, quality and compliance. To meet the growing demand for high-quality APIs for both clinical and commercial purposes, Bachem has established a comprehensive CMC development concept. This approach is tailored to each product, ensuring flexibility while maintaining rigorous standards. The concept involves a thorough analysis of process-related risks and ensures full alignment with both clinical timelines and regulatory guidelines.

Daniel is holding a Diploma in Biology and a PhD in Medicinal Biochemistry. He worked for 6 years as Postdoctoral Researcher in Molecular Cell Biology and Tumor Biology before he joined Bachem in 2013. As Senior Group Leader in Global Project Management, Daniel is heading a group of six Project Managers, focusing on CMC Development of Peptide APIs.